MD Anderson

Running trials

• Not yet recruiting

  A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

  NCT07722767· Phase 1· Source

• Recruiting

  A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT07336472· Phase 1/2· Source

• Recruiting

  First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

  NCT07756281· Phase 1· Source

• Recruiting

  SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

  NCT07857616· Phase 1· Source

• Recruiting

  A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  NCT07277413· Phase 1· Source

• Recruiting

  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

  NCT07503808· Phase 1· Source

• Recruiting

  Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

  NCT07154706· Phase 3· Source

• Recruiting

  A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  NCT06859424· Phase 2· Source

• Recruiting

  A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

  NCT06907043· Phase 1/2· Source

• Active, not recruiting

  Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

  NCT06736418· Phase 1· Source

• Recruiting

  Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

  NCT06786533· Phase 1· Source

• Recruiting

  A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  NCT06774963· Phase 1· Source

• Recruiting

  A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  NCT05980806· Phase 2· Source

• Recruiting

  Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  NCT06128551· Phase 1/2· Source

• Recruiting

  TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

  NCT05848687· Phase 1/2· Source

• Active, not recruiting

  A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

  NCT05787587· Phase 1· Source

• Recruiting

  Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

  NCT04953910· Phase 1· Source

• Recruiting

  Metastatic Leiomyosarcoma Biomarker Protocol

  NCT05653388· Source

• Active, not recruiting

  A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

  NCT05481151· Phase 3· Source

• Active, not recruiting

  A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

  NCT05453903· Phase 1· Source

• Recruiting

  A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  NCT05377996· Phase 1/2· Source

• Recruiting

  Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  NCT05320198· Phase 1/2· Source

• Active, not recruiting

  A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

  NCT05141721· Phase 2/3· Source

• Recruiting

  Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

  NCT04953897· Phase 1· Source

• Recruiting

  A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy

  NCT04678011· Source

• Recruiting

  CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  NCT05143996· Phase 1/2· Source

• Recruiting

  A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

  NCT04913285· Phase 1· Source

• Active, not recruiting

  An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  NCT04720157· Phase 3· Source

• Recruiting

  A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

  NCT04811560· Phase 1/2· Source

• Recruiting

  Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  NCT04588922· Phase 1/2· Source

• Active, not recruiting

  Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

  NCT04794699· Phase 1· Source

• Active, not recruiting

  Evolutionary Therapy for Rhabdomyosarcoma

  NCT04388839· Phase 2· Source

• Recruiting

  A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

  NCT04677998· Source

• Active, not recruiting

  Olaparib With Ceralasertib in Recurrent Osteosarcoma

  NCT04417062· Phase 2· Source

• Active, not recruiting

  Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

  NCT03915184· Phase 1/2· Source

• Active, not recruiting

  SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

  NCT03161431· Phase 1· Source

• Active, not recruiting

  Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

  NCT03836352· Phase 2· Source

• Recruiting

  Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

  NCT03422198· Phase 3· Source

• Active, not recruiting

  Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

  NCT02947685· Phase 3· Source

• Recruiting

  Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

  NCT03013998· Phase 2/3· Source

• Active, not recruiting

  Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT02227251· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukemia8 recruiting
• Lung cancer7 recruiting
• Childhood cancers6 recruiting
• Endometrial cancer5 recruiting
• Myelodysplastic syndromes5 recruiting
• Ovarian cancer4 recruiting
• Pancreatic cancer4 recruiting
• Gastric and esophageal cancer3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Melanoma2 recruiting
• Sarcoma2 recruiting
• Triple-negative breast cancer2 recruiting
• Bladder cancer1 recruiting
• Head and neck cancer1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  EO4010 in Previously Treated Metastatic Colorectal Carcinoma

  NCT05589597· Phase 1/2· Source

• Terminated

  EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer

  NCT05350501· Phase 2· Source

• Terminated

  POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)

  NCT05299606· Source

• Completed

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Source

• Terminated

  Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

  NCT05126433· Phase 2· Source

• Completed

  HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

  NCT04975698· Phase 2· Source

• Completed

  CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

  NCT04681131· Phase 2· Source

• Completed

  Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

  NCT04641871· Phase 1· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· Source

• Completed

  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

  NCT04109456· Phase 1· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Source

• Terminated

  A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

  NCT03901469· Phase 2· Source

• Completed

  Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

  NCT03939026· Phase 1· Source

• Completed

  A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT03900598· Phase 1· Source

• Terminated

  A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

  NCT03547115· Phase 1· Source

• Recruiting

  Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response

  NCT04134780· Source